DRV eq. 400mg base / r 50mg, tab.

STD DORADRVR45T

Valid Article

6.4.2.3 - Protease inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AR26
Anatomical Therapeutic Chemical Classification according to WHOCC
The order of this product needs to be justified and is only acceptable under certain conditions.
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
The product is part of at least one Kit. A kit is a collection of products (medical and/or logistic) that are needed for a certain intervention in emergency. The choice and quantity of the articles reflects the MSF protocols for this specific situation. The use of Kits allows to start an intervention without a detailed evaluation.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

See Related

Add article to list

   

Add Kit To Wishlist

   

DARUNAVIR (DRV) / RITONAVIR (r)

Therapeutic Action

Fixed-dose combination (FDC) of two antiretrovirals, protease inhibitors (PI)

Indications

Third-line antiretroviral therapy (ART) regimen

Indicated in HIV patients after failure of a previous lopinavir/ritonavir-based ART regimen.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

The fixed-dose combination (FDC) is the preferred option. It replaces the regular tablets of darunavir and ritonavir.

Precautions for Use

Darunavir in combination with ritonavir reduces the efficacy of implants and oral contraceptives: use injectable medroxyprogesterone or an intrauterine device.

Storage

Below 25ºC